Human antibodies that bind cd22 and uses thereof

Abstract

The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

1 . A method of treating a CD22-expressing cancer, comprising administering to a subject a human monoclonal antibody which specifically binds to CD22, or antigen-binding portion thereof, in an amount effective to treat the cancer. 
     
     
         2 . The method of  claim 1 , wherein the cancer is a B cell lymphoma. 
     
     
         3 . The method of  claim 2 , wherein the B cell lymphoma is a non-Hodgkin's lymphoma. 
     
     
         4 . The method of  claim 1 , wherein the cancer is selected from Burkitt's lymphoma and B cell chronic lymphocytic leukemia. 
     
     
         5 . The method of  claim 1 , wherein the subject is human. 
     
     
         6 . A method of inhibiting growth of a CD22-expressing tumor cell, the method comprising contacting the CD22-expressing tumor cell with a human monoclonal antibody which specifically binds to CD22, or antigen-binding portion thereof, such that growth of the CD22-expressing tumor cell is inhibited. 
     
     
         7 - 8 . (canceled) 
     
     
         9 . The method of  claim 1 , wherein the antibody, or antigen-binding portion thereof, comprises:
 (a) a heavy chain variable region CDR1 comprising SEQ ID NO:2;   (b) a heavy chain variable region CDR2 comprising SEQ ID NO:6 or SEQ ID NO:60;   (c) a heavy chain variable region CDR3 comprising SEQ ID NO: 10;   (d) a light chain variable region CDR1 comprising SEQ ID NO:14;   (e) a light chain variable region CDR2 comprising SEQ ID NO:20; and   (f) a light chain variable region CDR3 comprising SEQ ID NO:26.   
     
     
         10 . The method of  claim 9 , wherein the antibody, or antigen-binding portion thereof, comprises:
 (a) a heavy chain variable region CDR1 comprising SEQ ID NO:2;   (b) a heavy chain variable region CDR2 comprising SEQ ID NO:6;   (c) a heavy chain variable region CDR3 comprising SEQ ID NO: 10;   (d) a light chain variable region CDR1 comprising SEQ ID NO:14;   (e) a light chain variable region CDR2 comprising SEQ ID NO:20; and   (f) a light chain variable region CDR3 comprising SEQ ID NO:26.   
     
     
         11 . The method of  claim 9 , wherein the antibody, or antigen-binding portion thereof, comprises:
 (a) a heavy chain variable region CDR1 comprising SEQ ID NO:2;   (b) a heavy chain variable region CDR2 comprising SEQ ID NO:60;   (c) a heavy chain variable region CDR3 comprising SEQ ID NO: 10;   (d) a light chain variable region CDR1 comprising SEQ ID NO:14;   (e) a light chain variable region CDR2 comprising SEQ ID NO:20; and   (f) a light chain variable region CDR3 comprising SEQ ID NO:26.   
     
     
         12 . The method of  claim 9 , wherein the antibody, or antigen-binding portion thereof, comprises:
 (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:32 or 61; and   (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO:36.   
     
     
         13 . The method of  claim 12 , wherein the antibody, or antigen-binding portion thereof, comprises:
 (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:32; and   (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO:36.   
     
     
         14 . The method of  claim 12 , wherein the antibody, or antigen-binding portion thereof, comprises:
 (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:61; and   (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO:36.   
     
     
         15 . The method of  claim 1 , wherein the antibody, or antigen-binding portion thereof, cross-competes for binding to CD22 with a reference antibody, wherein the reference antibody comprises:
 (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:32 or 61; and   (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO:36.   
     
     
         16 . The method of  claim 1 , wherein the antibody is a full-length antibody of an IgG1 isotype or an IgG4 isotype. 
     
     
         17 . The method of  claim 1 , wherein the antibody or antigen-binding portion thereof, is linked to a therapeutic agent. 
     
     
         18 . The method of  claim 17 , wherein the therapeutic agent is a cytotoxin or a radioactive agent. 
     
     
         19 . The method of  claim 17 , wherein the therapeutic agent is conjugated to the antibody by a chemical linker. 
     
     
         20 . The method of  claim 19 , wherein the chemical linker is selected from the group consisting of peptidyl linkers, hydrazine linkers, and disulfide linkers. 
     
     
         21 . The method of  claim 1 , wherein the antibody is administered by a route selected from subcutaneously, intravenously, intramuscularly, intradermally, and intraperitoneally. 
     
     
         22 . The method of  claim 1 , further comprising administering to the subject a second anti-neoplastic agent.